Privia Health Group (NASDAQ:PRVA) Price Target Raised to $35.00

Privia Health Group (NASDAQ:PRVA) had its price objective upped by Canaccord Genuity Group from $34.00 to $35.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 44.00% from the stock’s previous close.

A number of other analysts also recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Privia Health Group from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Stephens reaffirmed an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research note on Thursday, December 4th. Piper Sandler reissued an “overweight” rating and issued a $36.00 price target on shares of Privia Health Group in a research note on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 price objective on shares of Privia Health Group in a research report on Thursday. Finally, Citizens Jmp boosted their target price on shares of Privia Health Group from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Privia Health Group currently has a consensus rating of “Moderate Buy” and an average price target of $30.79.

Privia Health Group Stock Down 2.4%

Privia Health Group stock traded down $0.61 during mid-day trading on Friday, hitting $24.31. 797,661 shares of the stock were exchanged, compared to its average volume of 770,596. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of 187.06, a PEG ratio of 1.59 and a beta of 0.83. Privia Health Group has a 12 month low of $18.77 and a 12 month high of $26.51. The firm’s fifty day simple moving average is $23.06 and its two-hundred day simple moving average is $23.44.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.21. Privia Health Group had a net margin of 0.89% and a return on equity of 2.52%. The company had revenue of $541.17 million during the quarter, compared to analysts’ expectations of $516.61 million. During the same period in the prior year, the company posted $0.21 earnings per share. Privia Health Group’s revenue for the quarter was up 17.4% compared to the same quarter last year. As a group, analysts forecast that Privia Health Group will post 0.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Privia Health Group news, Director Matthew Shawn Morris sold 13,647 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the sale, the director directly owned 68,188 shares of the company’s stock, valued at approximately $1,705,381.88. The trade was a 16.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David Mountcastle sold 23,887 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.03, for a total value of $597,891.61. Following the completion of the transaction, the chief financial officer owned 172,909 shares in the company, valued at $4,327,912.27. This represents a 12.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 10.70% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

Large investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its holdings in shares of Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after purchasing an additional 926 shares during the last quarter. Global Retirement Partners LLC grew its position in Privia Health Group by 579.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after purchasing an additional 1,351 shares in the last quarter. CWM LLC increased its stake in Privia Health Group by 89.4% in the 2nd quarter. CWM LLC now owns 3,416 shares of the company’s stock valued at $79,000 after buying an additional 1,612 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in shares of Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after buying an additional 1,200 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Privia Health Group in the 4th quarter worth approximately $93,000. 94.48% of the stock is currently owned by institutional investors.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Strong quarter and full‑year beats — PRVA delivered Q4 revenue of $541.2M and reported EPS above consensus; full‑year 2025 results came in at or above the high end of guidance with adjusted EBITDA up ~38.8% and net income +59.3%. This supports the case for operational momentum and margin improvement. Privia Health Reports Fourth Quarter and Full‑Year 2025 Financial Results
• Positive Sentiment: Bullish analyst landscape — The mean of analyst price targets implies roughly ~25% upside from current levels, and multiple firms maintain buy/outperform ratings; that can support further upside if execution continues. Wall Street Analysts Think Privia Health (PRVA) Could Surge 25.45%
• Positive Sentiment: Aggressive 2026 guidance and expansion plan — Management is guiding to ~20% adjusted EBITDA growth at the midpoint for FY‑2026, expects to expand to 24 states and grow providers, and aims to convert ~80% of adjusted EBITDA into free cash flow. These targets point to continued top‑line and cash‑flow improvement if realized. Privia Health targets 19.5% adjusted EBITDA growth for 2026 while expanding national footprint to 24 states
• Neutral Sentiment: Investor materials available — Earnings transcript, slide deck and the conference call provide detail for modeling assumptions and customer mix; active investors will parse these for cadence of provider additions and MA/value‑based performance. Privia Health (PRVA) Q4 2025 Earnings Transcript
• Negative Sentiment: Non‑GAAP reconciling caveat and heavy stock‑based compensation — Management warned it cannot fully reconcile forward‑looking non‑GAAP measures to GAAP due to uncertain items, and 2025 included ~$71M of non‑cash stock comp; these increase execution and accounting transparency risk. Privia Health Reports Fourth Quarter and Full‑Year 2025 Financial Results
• Negative Sentiment: Insider selling and valuation watch — Recent disclosed insider sales and a high trailing P/E (background figures) may prompt profit‑taking; investors may also be cautious about stretched multiples if growth slows. QuiverQuant summary of Privia results

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.